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The diagnosis of arrhythmogenic cardiomyopathy is challenging especially in children at 
risk of adverse events. Analysis of cardiac junctional protein distribution may have 
diagnostic and prognostic implications but its utility is limited by the need for a heart 
sample. We previously reported that buccal mucosa cells show a similar pattern of protein 
redistribution to the myocardium of adult patients with ACM. To establish when junctional 
protein localization abnormalities first occur and whether they correlate with progression 
of clinically apparent disease, we analysed serial buccal mucosa samples of children and 
adolescents from families with known ACM-causing variants. We found that junctional 
protein re-localization does not correlate with the presence of an ACM-causing variant but 
instead correlates with the onset of disease. No changes are seen in buccal smears until 
there is clinical evidence of disease. In addition, progressive shifts in the distribution of 
some proteins correlate with worsening of the disease phenotype.  Finally, we observed 
restoration of junctional signal for Cx43, the major ventricular gap junction protein, in a 
patient with a favourable response to anti-arrhythmic therapy. Our results indicate that 
analysis of buccal mucosa cells, may be a totally safe, inexpensive and non-invasive tool 
for risk stratification and potentially monitoring response to treatment in children from 
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Arrhythmogenic cardiomyopathy (ACM) is a familial myocardial disease characterized by a 
high incidence of ventricular arrhythmias and sudden cardiac death particularly in young 
individuals and athletes.1  The diagnosis of ACM can be challenging because of variable 
age-related expression of disease and incomplete genetic penetrance.  This is especially 
true for the prospective identification of children and young adults at risk of adverse 
events.  
ACM is often caused by variants in genes encoding proteins in desmosomes, cell-cell 
adhesion organelles in myocardial intercalated disks.3  Several studies have demonstrated 
reduced amounts of immunoreactive signal for selected desmosomal proteins, gap 
junction proteins and ion channel proteins at intercalated discs in myocardium from ACM 
patients.  The most consistent reductions, seen in hearts of patients with classical right 
ventricular disease, involve the desmosomal protein plakoglobin and the major ventricular 
gap junction protein connexin43 (Cx43).4-6  The diagnostic and/or prognostic significance 
of such changes is the subject of ongoing investigation but the potential clinical utility of 
this approach is severely limited by the need for myocardial tissue for analysis.  
Recognizing that pathogenic variants in desmosomal genes cause disease in heart and 
skin,7 we previously investigated whether buccal mucosa cells, which can be easily and 
safely obtained at minimal cost, could be used as a surrogate for myocardium in ACM 
patients.  We found that immunoreactive signals for plakoglobin and Cx43 were 













junctional signal for the desmosomal protein desmoplakin was reduced in buccal cells 
from patients with pathogenic variants in DSP, DSG2 or DSC2 but not PKP2 or JUP, 
whereas signal for the desmosomal protein plakophilin-1 (an isoform of plakophilin-2 
expressed in outer stratified squamous epithelial cells) was depressed in patients with 
variants in PKP2 but not in other desmosomal genes.8  
The earliest clinical manifestations of ACM do not usually become apparent until young 
adulthood or later.2  It is not known, however, when changes in the distribution of cell-cell 
junction proteins first occur or whether they correlate with the onset or progression of 
clinically apparent disease.  To address this question, we have analysed buccal mucosal 
cells in children and adolescents from families with documented ACM variants.  We found 
that changes in cell-cell junction proteins track with the clinical phenotype.  No changes in 
junctional protein localization were seen in buccal smears until and unless there was 
evidence of disease.  In addition, progressive shifts in the distribution of some proteins 
correlated with worsening of the disease phenotype.  We also observed restoration of 
junctional Cx43 signal in one patient in response to bisoprolol treatment.  These results 
suggest that analysis of buccal cells may be a safe, inexpensive and non-invasive tool to 
predict prognosis and potentially assess efficacy of pharmaceutical interventions in 
children and adolescents from families that carry pathogenic variants linked to ACM.  
METHODS AND MATERIALS:  













Buccal mucosa smears were prepared from 12 children or adolescents (age range: 3-18) 
with a family history of ACM who were being clinically evaluated at the Great Ormond 
Street Hospital (GOSH) Centre for Inherited Cardiovascular Disease, London or the Nikos 
Protonotarios Medical Centre in Naxos, Greece.  These individuals undergo 
comprehensive annual clinical phenotyping including resting, ambulatory and exercise 
electrocardiography (ECG); signal-averaged ECG (SA-ECG); advanced echocardiography 
and cardiac magnetic resonance imaging (MRI).  Buccal smears were obtained during 
these annual hospital visits.  All but one of these patients had documented pathogenic 
variants in desmosomal genes (JUP, PKP2, DSP, DSG2) including 8 with heterozygous 
dominant variants, 1 with compound heterozygous variants in DSP, and 1 each with 
homozygous recessive variants in JUP or PKP2. The remaining child showed no known 
pathogenic variants in a 96-gene cardiomyopathy panel. Gene variants in desmosomal 
genes, when identified, were classified as variants of uncertain significance (VUS), likely 
pathogenic or pathogenic using American College of Medical Genetics (ACMG) consensus 
guidelines. VUS with family history of ACM were considered as likely 
pathogenic/pathogenic in this study. Buccal smears were also obtained from 13 healthy 
children (age range: 3-18) with no clinical manifestations or family history of heart disease 
who served as normal controls.  All subjects and/or their parents/guardians provided 
written informed consent.  Sample collection protocols were approved by the National 
Health Service Health Research Authority (NHS/HRA) in the United Kingdom and 













followed and database information was stored in password-encrypted files.  All buccal 
mucosa samples were coded and analysed in a blinded fashion. The majority of the study 
participants were swabbed twice with an average interval of 12-18 months between 
sampling.  
Buccal mucosa sampling and preparation of smears:  
Clean, individually-wrapped cytology brushes were used for collection of buccal cells.  
Material was collected from the inside of the cheek by using slight rolling and scraping 
motions for about 30 seconds on each side.  Immediately after collection, the buccal 
mucosa material was smeared on positively-charged microscopy slides, which were 
sprayed with a fixative (M-FIX, Merck) from a distance of ~30 cm. The slides were allowed 
to air-dry and stored at room temperature before being immunostained.  
Immunohistochemistry:  
Buccal mucosa smears were immunostained with the following primary antibodies using 
established protocols:  mouse monoclonal anti-plakoglobin (P8087, Sigma Aldrich), mouse 
monoclonal anti-plakophilin-1 (325700, Thermo Fisher Scientific), mouse monoclonal anti-
desmoplakin (10R-D108AX, Fitzgerald) and mouse polyclonal anti-Cx43 (C8093, Sigma 
Aldrich ).  Slides were then incubated with Cy3-conjugated secondary antibodies (Jackson 
ImmunoResearch) for 2 hours at room temperature and counterstained with DAPI to label 














We optimized our immunostaining protocol for each protein by first determining the 
lowest primary antibody concentration that produced strong signal in control buccal 
mucosa cells.  These conditions were then applied throughout the study to determine 
whether cells from subjects from ACM families showed apparent reduction in junctional 
signal.  Using this approach, we consistently observed either control levels of signal or a 
virtual absence of junctional signal for any given primary antibody.   This ‘binary’ approach 
ensures reproducibility of our results and precludes the need for signal quantification.  
Each batch of ACM samples was immunostained alongside freshly-obtained smears from 
age-matched controls.  
RESULTS:  
Immunoreactive signals for selected junction proteins are reduced in buccal mucosa 
cells in children with clinical ACM 
To determine whether changes in the distribution of cell-cell junction proteins occur in 
buccal mucosa cells in children with clinically manifest ACM, as previously observed in 
adults,8 we analysed buccal smears from 3 children with documented ACM and 
pathogenic variants in desmosomal genes (Group A, Table 1).  Patient 1 (currently 12 years 
of age) developed woolly hair and palmoplantar keratoderma during the first year of life.  
He was evaluated at age 2 years after genetic testing revealed compound heterozygosity 
for a Ser711fsX4 frameshift and a Arg2586X nonsense variant in DSP.  Cardiomyopathy 













he had dilated cardiomyopathy (DCM) with significant left ventricular (LV) dilatation and 
systolic impairment on echocardiography and non-sustained ventricular tachycardia 
(NSVT) on Holter monitoring, in addition to a recent history of recurrent syncope.  When 
the second buccal swab was obtained (2020) his condition was stable without significant 
progression of disease.  Analysis of both sets of buccal smears showed strong membrane 
immunoreactive signals for plakoglobin and  plakophilin-1 but severely depressed signals 
for desmoplakin and Cx43 compared to age-matched controls (Fig 1).  
Patient 2 (currently 9 years of age) was diagnosed with ACM following presentation with 
symptoms of heart failure.  Genetic screening identified homozygosity for the variant PKP2 
p.Lys859Asn.  At the time her buccal cells were obtained (2021), she showed severe 
biventricular dysfunction on echocardiography and cardiac MRI and NSVT on Holter monitoring 
requiring placement of a defibrillator (ICD).  Analysis of her buccal smears showed strong 
membrane immunoreactive signal for plakophilin-1 but significantly depressed signals for 
plakoglobin, Cx43 and desmoplakin compared to age-matched controls (Fig 1).  
Patient 3 (currently 9 years of age) was first evaluated at age 6 years.  He had a strong maternal 
history of ACM.  His mother suffered an out-of-hospital cardiac arrest despite a non-diagnostic 
clinical assessment prior to the event.  Genetic screening identified a nonsense variant DSP 
p.Arg84X.   At the time buccal cells were obtained (in 2019 and 2021), the child showed left axis 
deviation on ECG but no structural abnormalities by imaging modalities.  Analysis of both sets 













plakophilin-1 but clearly depressed signal for desmoplakin compared to age-matched control 
(Fig 1). 
Buccal cell-cell junction protein localization is normal in unaffected children carrying ACM 
variants 
Previous studies of myocardial junctional protein distribution have involved ACM patients who 
fulfilled diagnostic criteria and exhibited clinical manifestations of disease or who died suddenly 
and were diagnosed with ACM at autopsy.4-6 Ethical considerations preclude myocardial 
sampling in subjects who carry ACM variants but are otherwise normal.  To determine whether 
cell-cell junction proteins are mislocalized in children before clinical abnormalities arise, we 
analysed serial buccal mucosa smears from 6 unaffected children with desmosomal gene 
variants.  
Patient 4 (currently 5 years of age) was first evaluated at age 14 months for hyperkeratotic 
palmar and plantar skin lesions which appeared in the second month of life.  This was 
associated with woolly hair and curled eyelashes (Fig 2).  Genetic analysis showed 
homozygosity for frameshift variant JUP p.Trp680GlyfsX11 known to cause Naxos disease.  
Buccal cells were first obtained when the child was 3 years of age, at which time his physical 
examination, 12-lead ECG, 24-hour Holter monitor and transthoracic echocardiography were all 
normal.  Analysis of the smears showed normal immunoreactive signals for plakoglobin, Cx43, 
desmoplakin and plakophilin-1 (Fig 3).  
Patient 5 (currently 16 years of age) was first evaluated at age 9 years.  His father had 













is predicted to cause abnormal mRNA splicing.  Patient 6 (currently 12 years of age) was first 
evaluated at age 10 years.  He has a missense variant DSG2 p.Thr335Ala.  A maternal uncle had 
clinically manifest ACM with an ICD.  His mother carries the DSG2 variant and had a positive SA-
ECG but showed no structural abnormalities on imaging modalities.  Patient 7 (currently 18 
years of age), first evaluated at age7 years, has a splice acceptor variant PKP2 c.2146-1G>C.  Her 
father, a carrier of the same PKP2 variant, has ACM and an ICD.  Patients 8 and 9 are siblings, 
currently 12 and 13 years of age, respectively.  First evaluated aged 9 and 10, they both have a 
frameshift variant PKP2 p.Thr50SerfsX61.  Their father and paternal grandfather carry the same 
pathogenic variant and both had been diagnosed with ACM.   All of these children undergo 
annual electrocardiographic and imaging studies and none showed any abnormalities at the 
times buccal cells were obtained.  Repeat buccal smears were prepared from each of them 12-
18 months apart.  All showed normal distribution for plakoglobin, Cx43, desmoplakin and 
plakophilin-1.  Demographic information and mutation status for these children are included in 
Table 1 (Group B) and representative confocal immunofluorescence images are shown in Figure 
3.  
Changes in buccal cell-cell junction protein distribution correlate with onset of ACM clinical 
manifestations and pharmacological intervention 
Patient 10 (currently 16 years of age) was first evaluated at age 3 years.  His father had been 
diagnosed with ACM and received an ICD following a cardiac arrest.  Both father and son were 
found to have a splice variant PKP2 c.2146-1 G>C, predicted to affect the acceptor splice site of 
intron 10.  At age 14, the patient’s ECG showed minor intraventricular conduction delay and T-













although imaging studies did not show any abnormalities.  Immunohistochemical analysis of his 
buccal smears at this time showed normal distribution for plakoglobin, desmoplakin and 
plakophilin-1 but severely depressed immunoreactive signal for Cx43 (Fig 4, swab 1).  When he 
was next evaluated at GOSH in 2021, his ECG showed fractionated QRS complexes in leads V1 
and V2 with T-waves upright from V2 to V6.  SA-ECG was positive for late potentials in all three 
vectors.  On echocardiogram, there was mild left ventricular dilatation but with good 
biventricular systolic and diastolic function.  Immunohistochemical analysis of a second set of 
buccal smears showed normal localization of desmoplakin but in contrast with the first set of 
samples, signals for plakoglobin, Cx43 and plakophilin-1 were now severely depressed (Fig 4, 
swab 2).   
Patient 11 (currently 10 years of age) was first evaluated at age 5 years and given a diagnosis of 
erythrokeratoderma-cardiomyopathy syndrome.  She was found to have a de novo missense 
mutation DSP p.Leu622Pro. At age 9, she showed a severe phenotype of ACM with frequent 
ventricular ectopic beats, biventricular dilatation and impaired LV systolic function (EF: 48%).  
Immunohistochemical analysis of her buccal smears at this time showed normal distribution for 
plakoglobin, desmoplakin and plakophilin-1 but severely depressed immunoreactive signal for 
Cx43 (Fig 4, swab 1).   A year later, there was a significant increase in ventricular ectopy and 
triplets were evident on ECG and 24-hour Holter monitoring.  Echocardiography showed 
deterioration of systolic function and the EF was reduced to 38%.   Worsening of both the 
arrhythmic and contractile phenotypes prompted implantation of an ICD and initiation of 
treatment with bisoprolol.  Analysis of the second set of buccal smears showed normal 













immunoreactive signal for the mutant protein desmoplakin was now severely depressed.  
Interestingly, localization of Cx43 appeared normal with strong signal present on buccal cell 
membranes (Fig 4, swab 2).  Restoration of junctional Cx43 signal was associated with absence 
of ventricular ectopy on ECG at the time the second buccal mucosa sample was obtained. 
Moreover, Holter monitoring showed a reduction from an 8.2% arrhythmic burden (482 
couplets, 8 triplets) at the time of the first swab to a 1.8% arrhythmic burden (26 couplets, 1 
triplet) 6 weeks following establishment of an 2.5 mg daily dosage of bisoprolol.  
Patient 12 (currently 17 years of age) was first evaluated at age 16 years after developing 
symptoms of syncope and palpitations.  She was found to have severe clinical manifestations of 
ACM including frequent syncopal/pre-syncopal episodes and persistent atrial flutter.  Imaging 
studies showed a moderately dilated RV with impaired systolic function and an RVOT aneurysm.  
The LV was mildly dilated with preserved systolic function.  Immunohistochemical analysis of 
her buccal smears at this time showed normal distribution for desmoplakin and plakophilin-1 
while immunoreactive signals for plakoglobin and Cx43 were severely depressed at buccal cell 
membranes (Fig 4, swab 1).  She subsequently underwent atrial flutter ablation.  
Echocardiography a year after the initial buccal swab showed impaired biventricular systolic 
function with an EF of 45-50%, septal dyskinesia and regional wall motion abnormalities at the 
apex.  Immunohistochemical analysis of a second set of buccal smears showed normal 
localization for desmoplakin but this time in addition to plakoglobin and Cx43 immunoreactive 
signals being depressed, signal for plakophilin-1 was also severely depressed (Fig 4, swab 2).  
The patient has undergone genetic testing but no pathogenic variants were identified on a 96-













are included in Table 1 (Group C).  A summary of immunohistochemical findings in buccal 
mucosa smears of children in all three groups is presented in Table 2.  
DISCUSSION: 
Loss of desmosomal, gap junction and ion channel proteins at myocardial intercalated disks has 
been reported in ACM patients and in many experimental models of the disease.4-6, 9-11  While it 
is likely that reduced electrical coupling and altered ion channel function contribute to 
arrhythmogenesis in ACM, the pathogenic implications of redistribution of desmosomal 
proteins are not so apparent.  It is known, however, that desmosomal proteins participate, 
directly or indirectly, in major cell signalling pathways including Wnt/β-catenin and Hippo/Yap 
cascades in which alterations have been implicated in the pathogenesis of ACM.12,13   The 
extent to which abnormal cell signalling may contribute to myocardial injury in ACM is not well 
understood but reduced immunohistochemical staining for junctional proteins appears to be a 
consistent feature of established disease.4-6, 9  
Because of the limited availability of myocardial tissue samples in ACM patients and ethical 
concerns about obtaining heart biopsies from gene carriers with no apparent disease, it has not 
been possible to correlate changes in the distribution of cell junction proteins with the onset 
and/or progression of clinical disease or responses to therapy.  This is especially true for 
children and adolescents who carry ACM disease alleles.  Using buccal mucosa cells as a 
surrogate for myocardium provides an opportunity to investigate these questions.  Here, we 
show that changes in protein localization in buccal cells correlates with clinical onset of disease.  













normalization of junctional Cx43 signal was associated with a significant reduction in ventricular 
ectopy following therapy (78% drop in arrhythmic burden), albeit only in one patient.   While 
these observations do not prove that redistribution of desmosomal proteins plays a pathogenic 
role in the onset and progression of ACM, there appears to be a correlation between changes in 
protein localization at the cell surface and clinical expression of disease.  Thus, serial buccal 
mucosal sampling might be a safe and inexpensive addition to the usual screening studies used 
in following ACM gene carriers at risk of developing clinical disease and an independent means 
of assessing response to therapy. 
Some observations reported here in children and adolescents differ from our previous studies 
in adults with ACM.  For example, in the present study we found normal protein distribution in 
5 children who carried pathogenic variants but showed no overt disease, whereas we 
previously saw reduced junctional signals for plakoglobin and Cx43 in buccal mucosa cells from 
3 adults who also carried variants but appeared well.8  A possible explanation for this difference 
may be related to patient age.   Alternatively, the adult gene carriers in the previous study may 
have exhibited subtle disease features at the time their buccal smears were analysed, as they 
had not been monitored with the same comprehensive clinical evaluations performed in 
children in the present study.       
We also saw some minor differences in patterns of protein distribution in adults and children 
with overt ACM.  For example, affected adults with DSP variants showed reduced signal for 
desmoplakin but not plakophilin-1, while patients with PKP2 variants showed depressed signal 
for plakophilin-1 but not desmoplakin.8  We saw the same results in the present study in 4 of 5 













normal plakophilin-1 signal but reduced desmoplakin signal.  However, this child was 
homozygous for a recessive C-terminal variant in PKP2 whereas the adults in the previous study 
were all heterozygous for variants in PKP2 associated with typical right ventricular disease.  
Thus, the severity of biophysical impact of a pathogenic variant, which is likely related to 
zygosity, could determine the specific pattern of abnormal protein distribution observed in 
buccal mucosa cells.   Finally, loss of junctional plakoglobin signal in buccal mucosa cells was 
seen previously in all ACM adults regardless of the underlying variant,4, 8 but 3 symptomatic 
children with DSP  variants (cases 1, 3 and 11) showed normal plakoglobin signal (associated 
with abnormalities in other junctional proteins).  One possible explanation for this difference is 
that the mutant protein (desmoplakin) might shift first from the membrane (as was seen in case 
11) and changes in plakoglobin eventually follow.  Alternatively, patterns of protein 
redistribution may vary in patients who show different clinical and pathological patterns of 
disease.  Most previous studies of junctional protein redistribution in heart and buccal cells 
involved patients with classic right ventricular disease, the great majority of whom showed 
reduced signal for plakoglobin.  However, DSP variants have been increasingly linked to 
biventricular or left-dominant ACM.  A recent report described two DSP variant carriers with 
subclinical ACM who showed loss of desmoplakin but not plakoglobin signals in endomyocardial 
biopsies.14  Similarly, a skin biopsy from a child with two DSP variants showed abnormal 
desmoplakin signal but normal plakoglobin distribution.15   Indeed, a recent study of 107 
patients with pathogenic DSP variants proposed that they exhibit “desmoplakin 













Analysis of serial buccal smears allowed correlation of changes in protein distribution with 
progression of clinical disease or in a single case, in response to therapy.  For example, we 
observed initial loss of Cx43 signal and subsequent loss of one or more desmosomal proteins in 
two patients (cases 10, 11) whose heart disease progressed.   This sequence may reflect the 
well documented clinical scenario in which ventricular ectopy is the initial clinical expression of 
disease with eventual progression to more severe features associated with structural 
remodelling of the heart. We also observed restoration of junctional Cx43 signal in a patient 
who showed frequent ventricular ectopy when the initial buccal smear was obtained but had 
responded to therapy and showed a significantly reduced arrhythmic burden when a repeat 
sample was analysed.  Although this hypothesis is based on observations rising from a single 
patient, there have been several studies in the past reporting drug modulation of gap junction 
remodelling.  Dhein et al. showed that although Cx43 localizes at the lateral membranes in the 
left atrium of atrial fibrillation (AF) patients not receiving beta-blockers, it is shifted to the 
intercalated disks in those patients receiving metoprolol. 17 In line with these findings, 
metoprolol and propranolol up-regulate the junctional localization of Cx43 in a rat model of 
myocardial infarction through miR-1 inhibition. 18-19 Finally, metoprolol increases Cx43 
expression in cultured cardiomyocytes without alterations in mRNA levels suggesting a post-
transcriptional regulatory mechanism.20 
A significant limitation of the present study is the small number of subjects that were analysed.  
ACM is a relatively rare disease, and is even less frequently manifest before adulthood. 
Moreover, even though performing a buccal smear is safe and painless, it is still challenging to 













study.   Additional work is certainly required to validate and extend the results of the present 
study.  Nevertheless, we report new observations about the relationship between junctional 
protein distribution in the buccal mucosa and disease manifestation in children of ACM families.  
This work may, thus, provide a rationale for future trials of buccal smears for monitoring 
children compared to usual care, and to gain further insights into disease mechanisms and 
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FIGURE LEGENDS:  
Figure 1: Representative images of buccal mucosa smears from a control and 3 children with a 
clinical presentation of ACM.  
Patient 1 (DSP mut) shows depressed immunoreactive signal for Cx43 and DSP but control-like 
signal for PG and PKP1. Patient 2 (PKP2 mut) shows depressed immunoreactive signal for PG, 
Cx43 and DSP but not PKP1 compared to age-matched controls. Patient 3 (DSP mut) shows 
depressed signal for DSP but control-like signal for PG, Cx43 and PKP1. Protein localization was 
unaltered between serial swabs. Cell nuclei (blue) are stained with DAPI. 
 
Figure 2: Cutaneous phenotype in a 18-year-old boy with Naxos disease (patient 4).  
Woolly hair (A), keratoderma over the tendon areas of the palms (B) and on the pressure areas 
of the soles (C). Eczematous lesions on the dorsal surface of the legs (D). 
 
Figure 3: Representative images of buccal mucosa smears from a control and 3 asymptomatic 
children bearing desmosomal gene mutations. 
Two of the children are bearing autosomal dominant mutations in PKP2 and one is homozygous 
for a recessive mutation in JUP. All children have no clinical manifestation of ACM and they 
showed normal distribution for PG, Cx43, DSP and PKP1 in their buccal epithelium, 
indistinguishable from controls in both sets of samples (~18 months apart). Cell nuclei (blue) 














Figure 4: Representative images of serial buccal smear samples from 3 children with ACM 
obtained ~18 months apart.  
All 3 children show changes in the localization of key junctional proteins over time correlating 










































  1 M 13 DSP 
c.2131_2132delAG p.Ser711CysfsX4 Frameshift Compound 
heterozygous 
Pathogenic 
 c.7756C>T p.Arg2586X Nonsense Pathogenic 
Group A 2 F 9 PKP2 c.2577G>T p.Lys859Asn Missense Homozygous Likely pathogenic 
  3 M 9 DSP c.250C>T p.Arg84X Nonsense Heterozygous Pathogenic 
  4 M 4 JUP c.2038_2039del p.Trp680GlyfsX11 Frameshift Homozygous Pathogenic 




Group B 6 M 12 DSG2 c.1003A>G p.Thr335Ala Missense Heterozygous VUS 




  8 F 12 PKP2 c.148_151delACAG p.Thr50SerfsX61 Frameshift Heterozygous Pathogenic 









































Table 2: Summary of immunohistochemical findings in buccal mucosa smears from patient groups A, B and C. 
 Patient # Sampling Plakoglobin Cx43 Desmoplakin PKP-1 
Group A 
1 
1st  Normal Depressed (↓) Depressed (↓) Normal 
2nd  Normal Depressed (↓) Depressed (↓) Normal 
2 
1st  Depressed(↓) Depressed (↓) Depressed (↓) Normal 
2nd  - - - - 
3 
1st  Normal Normal Depressed (↓) Normal 
2nd  Normal Normal Depressed (↓) Normal 
Group B 
4 
1st  Normal Normal Normal Normal 
2nd  Normal Normal Normal Normal 
5 
1st  Normal Normal Normal Normal 
2nd  Normal Normal Normal Normal 
6 
1st  Normal Normal Normal Normal 
2nd  Normal Normal Normal Normal 
7 
1st  Normal Normal Normal Normal 
2nd  Normal Normal Normal Normal 
8 
1st  Normal Normal Normal Normal 
2nd  Normal Normal Normal Normal 
9 
1st  Normal Normal Normal Normal 
2nd  Normal Normal Normal Normal 
Group C 
10 
1st  Normal Depressed (↓) Normal Normal 
2nd  Depressed (↓) Depressed (↓) Normal Depressed (↓) 
11 
1st  Normal Depressed (↓) Normal Normal 
2nd  Normal Normal Depressed (↓) Normal 
12 
1st  Depressed (↓) Depressed (↓) Normal Normal 
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Herein we analysed buccal mucosal cells from children of ACM families and showed that 
redistribution of key proteins occurs only when clinical features of ACM become manifest. We 
showed that additional shifts in protein distribution associate with deterioration of the disease and 
finally we observed restoration of signal for Cx43, the major gap junction protein, in response to 
anti-arrhythmic therapy. Our results indicate that analysis of buccal cells may be a safe, inexpensive 
and non-invasive tool for risk stratification and monitoring response to treatment in children 
bearing ACM-causing mutations. 
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